Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.47 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8100144 | 0.90 | DRD2 (0.54) | DRD2DRD4DRD3RAB9ANPC1 | |
| SCHEMBL3763682 | 0.87 | DRD2 (0.58) | DRD2DRD4DRD3RAB9ANPC1 | |
| SCHEMBL18295348 | 0.86 | TAAR1 (0.47) | DRD2DRD4DRD3SMN1; SMN2TAAR1 | |
| SCHEMBL17637581 | 0.85 | DRD2 (0.61) | DRD2DRD4DRD3RAB9ANPC1 | |
| SCHEMBL454009 | 0.84 | KDM4E (0.45) | SMN1; SMN2TAAR1CARM1PDIA6LTA4H | |
| Hydrochloric Acid SCHEMBL21595684 | 0.84 | MRGPRX4 (0.46) | SMN1; SMN2MEN1KMT2ATAAR1CARM1 | |
| SCHEMBL21601187 | 0.84 | CARM1 (0.45) | SMN1; SMN2TAAR1CARM1PDIA6LTA4H | |
| SCHEMBL3875286 | 0.84 | CARM1 (0.45) | DRD2DRD4DRD3RAB9ANPC1 | |
| SCHEMBL24456128 | 0.82 | SMN1; SMN2 (0.48) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30682440 | 0.82 | KMT2A (0.59) | DRD2RAB9ANPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-06-08 | — | — | US | disclosed |
| EP-0874805-B1 | PHENYLACETAMIDE DERIVATIVES | KOREA RES INST CHEM TECH (KR) | 2000-09-20 | — | — | EP | disclosed |
| US-5973201-A | ANALGESICS; ANTIINFLAMMATORY AGENTS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1999-10-26 | — | — | US | disclosed |
| EP-0874805-A1 | PHENYLACETAMIDE DERIVATIVES | Korea Research Institute of Chemical Technology (KR) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997021668-A1 | PHENYLACETAMIDE DERIVATIVES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1997-06-19 | — | — | WO | disclosed |
| US-4119729-A | TREATMENT OF HYPERTENSION | MEAD JOHNSON & COMPANY (US) | 1978-10-10 | — | — | US | disclosed |
| US-4067904-A | ANTIARRHYTHMIA, HYPOTENSIVE | MEAD JOHNSON & COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | DRD2 4877/4885DRD4 4878/4885DRD3 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.